HARROW, INC. Segments Disclosure

NOTE 19. SEGMENTS AND CONCENTRATIONS

 

The chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM does not review segment assets when assessing segment performance and deciding how to allocate resources. The Company reports on two reportable segments which were generally determined based on the decision-making structure of the Company and the grouping of similar products and services: Branded and ImprimisRx.

 

	●	The Branded segment includes activities of the Company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of our branded products.
	●	The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business.

 

The CODM evaluates segment performance and makes resource-allocation decisions primarily on the basis of segment contribution. Segment contribution is the internal measure of profitability that the CODM reviews on a regular basis to assess the operational performance of each segment, determine the appropriate level of sales and marketing investments, evaluate pricing decisions, and prioritize capital deployment among branded product initiatives and the ImprimisRx compounding operations.

 

Segment contribution for the segments represents net revenues less cost of sales, certain general and administrative expenses, selling and marketing expenses, and research and development expenses. The Company does not evaluate the following items at the segment level:

 

	●	Selling, general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal matters, public company costs (e.g. investor relations), Board of Directors and principal executive officers and other like shared expenses.
	●	Operating expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs.
	●	Other select revenues and operating expenses that are not segment specific including research and development expenses, amortization, and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments.

 

 

Segment net revenues, segment operating expenses and segment contribution information consisted of the following:

 

SCHEDULE OF SEGMENT NET REVENUES 

		Branded				ImprimisRx				Consolidated
		Year Ended December 31, 2025
		Branded				ImprimisRx				Consolidated
Product sales, net		$	195,362,000			$	76,547,000			$	271,909,000
Other revenues			394,000				-				394,000
Total revenues			195,756,000				76,547,000				272,303,000
Cost of sales			(37,230,000	)			(30,704,000	)			(67,934,000	)
Gross profit			158,526,000				45,843,000				204,369,000
Operating expenses:
Selling, general and administrative			86,324,000				29,373,000				115,697,000
Research and development			18,667,000				1,346,000				20,013,000
Segment contribution		$	53,535,000			$	15,124,000				68,659,000
Corporate											37,217,000
Research and development											927,000
Income from operations										$	30,515,000

 

		Year Ended December 31, 2024
		Branded				ImprimisRx				Consolidated
Product sales, net		$	115,120,000			$	83,499,000			$	198,619,000
Other revenues			995,000				-				995,000
Total revenues			116,115,000				83,499,000				199,614,000
Cost of sales			(21,667,000	)			(27,578,000	)			(49,245,000	)
Gross profit			94,448,000				55,921,000				150,369,000
Operating expenses:
Selling, general and administrative			62,301,000				23,607,000				85,908,000
Research and development			2,890,000				386,000				3,276,000
Segment contribution		$	29,257,000			$	31,928,000				61,185,000
Corporate											43,409,000
Research and development											8,954,000
Income from operations										$	8,822,000

 

		Year Ended December 31, 2023
		Branded				ImprimisRx				Consolidated
Product sales, net		$	37,512,000			$	79,935,000			$	117,447,000
Other revenues			12,746,000				-				12,746,000
Total revenues			50,258,000				79,935,000				130,193,000
Cost of sales			(12,662,000	)			(26,978,000	)			(39,640,000	)
Gross profit			37,596,000				52,957,000				90,553,000
Operating expenses:
Selling, general and administrative			18,126,000				29,210,000				47,336,000
Research and development			641,000				966,000				1,607,000
Segment contribution		$	18,829,000			$	22,781,000				41,610,000
Corporate											36,134,000
Research and development											5,045,000
Income from operations										$	431,000

 

Substantially all revenue is attributable to the U.S. All long-lived assets at December 31, 2025 and 2024 were located in the U.S.

 

 

Revenues by segment are further described as follows:

 SCHEDULE OF REVENUES BY SEGMENT

		For the Years Ended December 31,
			2025				%				2024				%				2023				%
IHEEZO		$	81,348,000				30	%		$	49,303,000				25	%		$	20,621,000				16	%
VEVYE			88,688,000				33	%			28,061,000				14	%			1,766,000				1	%
Other branded products			25,326,000				9	%			37,836,000				19	%			15,125,000				12	%
Other revenues, net			394,000				0	%			915,000				0	%			12,746,000				10	%
Branded revenue, net			195,756,000				72	%			116,115,000				58	%			50,258,000				39	%
ImprimisRx revenue, net			76,547,000				28	%			83,499,000				42	%			79,935,000				61	%
Total revenues, net.		$	272,303,000				100	%		$	199,614,000				100	%		$	130,193,000				100	%

 

Other than IHEEZO, VEVYE, and one ImprimisRx product, no other products accounted for more than 10% of total revenues for the periods presented.

 

Customer and Supplier Concentrations

 

Substantially all of the Company’s Branded sales are made to third-party distributors who sell the products to pharmacies and to the end-users. There were two customers who comprised more than 10% of the Company’s Branded revenues for the years ended December 31, 2025 and 2024 and one customer in 2023. There were no customers who comprised more than 10% of ImprimisRx revenues for the years ended December 31, 2025, 2024 and 2023. As of December 31, 2025 and December 31, 2024, accounts receivable from three customers and two customers accounted for 90% and 94%, respectively, of total consolidated accounts receivable.

 

The Company received its manufacturing supplies from three main suppliers during the years ended December 31, 2025 and 2023 and two main suppliers during the year ended December 31, 2024. These suppliers collectively accounted for 54%, 42% and 64% of manufacturing supplies purchases during the years ended December 31, 2025, 2024 and 2023, respectively.